All News
Filter News
Found 1,089 articles
-
Aadi Bioscience Announces Planned Leadership Transition - November 08, 2022
11/8/2022
Aadi Bioscience, Inc. announced the appointment of Neil Desai, Founder, President and CEO to Executive Chairman and Brendan Delaney, Chief Operating Officer, to President and CEO, effective as of January 1, 2023.
-
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
11/7/2022
bluebird bio, Inc. today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational progress.
-
Xencor Reports Third Quarter 2022 Financial Results
11/7/2022
Xencor, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a review of recent business and clinical highlights.
-
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
11/3/2022
Incyte will present data from its oncology portfolio at the upcoming 64th American Society of Hematology Annual Meeting, held December 10-13, 2022, in New Orleans and virtually.
-
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
11/3/2022
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and translational research data of lemzoparlimab, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022, in New Orleans, Louisiana.
-
With $120 million in backing, HI-Bio launched two assets licensed from MorphoSys AG, including the anti-CD38 antibody felzartamab and HIB210, aimed at severe immune-mediated diseases.
-
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
11/1/2022
Incyte (Nasdaq:INCY) today reports 2022 third quarter financial results, and provides a status update on the Company’s clinical development portfolio.
-
Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing
11/1/2022
Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, announced its launch with $120 million in financing.
-
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs
10/31/2022
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022.
-
GSK is pulling the plug on an experimental monoclonal antibody therapy for rheumatoid arthritis following a significant miss in one of three Phase III trials.
-
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
10/27/2022
MorphoSys AG announced that preliminary results from the ongoing Phase 1/2 study of tulmimetostat monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients.
-
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
10/27/2022
MorphoSys AG announced that its licensing partner, GSK plc, provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis.
-
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
10/21/2022
MorphoSys AG reported preliminary Monjuvi® U.S. net product sales for the third quarter of 2022 and provided an update to its financial guidance for 2022. Preliminary Monjuvi ® U.S. Net Product Sales are US$ 22.2 million for the third quarter of 2022 and US$ 64.1 million for the first nine months of 2022.
-
LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC
10/6/2022
LifeMine Therapeutics Inc. today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC. Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMine’s operations at its European offices in Basel, Switzerland.
-
Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market to Register Phenomenal Growth Rate By 2030 | Reports And Data
10/6/2022
The latest market analysis report published by Reports and Data, titled ‘Global Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market – Forecast to 2030,’ thoroughly examines the Diffuse Large B-Cell Lymphoma (DLBCL) Treatment industry to provide essential data & information for the targeted readers.
-
A look at the best spots for life science jobs globally.
-
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
9/28/2022
MorphoSys U.S. Inc. today announced data from the ongoing L-MIND study showing that Monjuvi® (tafasitamab-cxix) plus lenalidomide followed by Monjuvi monotherapy provided long-term efficacy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least 2 years, including six patients on treatment for 5 years or more.
-
High Demand For Mode Advanced Medications Is Expected To Drive Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market Growth By 2030 | Reports And Data
9/27/2022
The latest market analysis report published by Reports and Data, titled ‘Global Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market – Forecast to 2030,’ thoroughly examines the Diffuse Large B-Cell Lymphoma (DLBCL) Treatment industry to provide essential data & information for the targeted readers.
-
Increased Need For Effective Treatment Is Expected To Drive Colorectal Cancer (CRC) Treatment Market Growth By 2030 | Reports And Data
9/27/2022
The latest market analysis report published by Reports and Data, titled ‘Global Colorectal Cancer (CRC) Treatment Market – Forecast to 2030,’ thoroughly examines the Colorectal Cancer (CRC) Treatment industry to provide essential data & information for the targeted readers.
-
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.